A small group of scientists is working on what would have seemed like a fringe experiment ten years ago in a shared laboratory space in Oakland, California. It’s the kind of place with mismatched chairs, whiteboards covered in molecular diagrams, and the faint hum of centrifuges running in the adjacent room. They are working to create an open-source, streamlined process for producing insulin. Not a fresh insulin. Not one with a patent.
One that could be replicated from published instructions by a neighborhood pharmacy or a medical cooperative in a developing nation without having to pay license fees to any of the three businesses that presently control the majority of the world’s supply. Part of their funding comes from online donations of $10 or $25. Many of these donors are diabetics or family members of diabetics who have seen the rising cost of insulin for decades and have chosen to try something different.
Decentralized Science, or DeSci, is a loosely connected movement that operates on a fundamentally different set of assumptions than the traditional pharmaceutical industry. The Open Insulin Project is one node in a larger network of crowdfunding campaigns raising millions for open-source drugs. Patents are the foundation of conventional medication development.
A business develops a compound for years and billions of dollars, obtains a patent monopoly to recover those expenses, and sets prices that the market will accept. This is completely reversed by the open-source model: no patents are registered, all chemical structures, screening data, and trial results are instantly made public, and anybody who wishes to produce the final medication can do so, which lowers costs through competition. The theory is simple. The difficulties start during execution.
An early example of what this methodology may accomplish under duress was provided by the COVID Moonshot campaign, which was started during the pandemic when the lack of reasonably priced antivirals was a clear and pressing issue. Without submitting a single patent application, a global group of researchers crowdsourced structural data, conducted virtual molecular modeling in dozens of nations concurrently, and created a potential antiviral medication, making all of their discoveries accessible to any producer, anywhere.
Early on, it progressed more quickly than standard pharmaceutical timescales, in part because there was no governmental burden associated with intellectual property protection. Since then, VitaDAO and Gitcoin have applied a similar reasoning to longevity research, directing millions into open cellular biology protocols that larger institutions deem too speculative to touch through crypto-based quadratic funding, a mechanism that amplifies small donations through large matching pools. The extent of community involvement in these efforts is quite remarkable. The restrictions are just as real.
The early, high-risk discovery phase, where failure rates are high and rewards are speculative enough that most institutional money won’t touch it, is where crowdfunding excels at filling the gap that venture capital ignores. The leap from promising early science to the kind of thorough, large-scale clinical trial that regulatory bodies truly require is where it frequently falters. Tens of millions of dollars are spent on phase III trials. The bureaucratic grind of multi-year FDA review processes is rarely sustained by donation campaigns that spark enthusiasm for a notion.
Crowd Funded Cures has successfully navigated this by concentrating on off-patent medications being examined for novel uses. For example, using currently available generic antimalarials to test potential efficacy against colorectal cancer minimizes some of the development expense and regulatory complexity. However, even that strategy encounters obstacles that excitement cannot overcome on its own.
Observing these campaigns gain traction and then halt at the same recurring obstacles gives the impression that the movement has accurately identified a serious flaw in the financing and pricing of medicine, but that the remedy it is constructing still lacks essential infrastructure. The science may be transparent. It is possible to share the data.
The patents may remain unfiled. Whether a paradigm based on crowdsourcing and community goodwill can take a medication from discovery to a drugstore shelf without eventually requiring the kind of institutional support it was intended to replace is still up for debate.
